BRPI0907234B1 - Derivados de pirazolona-azo biciclo-substituído, seu uso, seu intermediário e seus processos de preparação, composição farmacêutica e deu uso - Google Patents

Derivados de pirazolona-azo biciclo-substituído, seu uso, seu intermediário e seus processos de preparação, composição farmacêutica e deu uso Download PDF

Info

Publication number
BRPI0907234B1
BRPI0907234B1 BRPI0907234-9A BRPI0907234A BRPI0907234B1 BR PI0907234 B1 BRPI0907234 B1 BR PI0907234B1 BR PI0907234 A BRPI0907234 A BR PI0907234A BR PI0907234 B1 BRPI0907234 B1 BR PI0907234B1
Authority
BR
Brazil
Prior art keywords
mixture
methyl
carboxylic acid
dihydro
mmol
Prior art date
Application number
BRPI0907234-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Hao Zheng
Yiqian Chen
Hongbo Fei
Shenglan Wang
Li Wang
Peng Cho Tang
Hejun Lü
Original Assignee
Jiangsu Hengrui Medicine Co., Ltd.
Shanghai Hengrui Pharmaceutical Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd filed Critical Jiangsu Hengrui Medicine Co., Ltd.
Publication of BRPI0907234A2 publication Critical patent/BRPI0907234A2/pt
Publication of BRPI0907234B1 publication Critical patent/BRPI0907234B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D231/08—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with oxygen or sulfur atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0907234-9A 2008-01-10 2009-01-04 Derivados de pirazolona-azo biciclo-substituído, seu uso, seu intermediário e seus processos de preparação, composição farmacêutica e deu uso BRPI0907234B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN200810000346.6 2008-01-10
CNA2008100003466A CN101481352A (zh) 2008-01-10 2008-01-10 双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用
PCT/CN2009/000001 WO2009092276A1 (zh) 2008-01-10 2009-01-04 双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用

Publications (2)

Publication Number Publication Date
BRPI0907234A2 BRPI0907234A2 (pt) 2020-08-04
BRPI0907234B1 true BRPI0907234B1 (pt) 2021-08-10

Family

ID=40878665

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0907234-9A BRPI0907234B1 (pt) 2008-01-10 2009-01-04 Derivados de pirazolona-azo biciclo-substituído, seu uso, seu intermediário e seus processos de preparação, composição farmacêutica e deu uso

Country Status (15)

Country Link
US (2) US8367710B2 (enExample)
EP (1) EP2236500B1 (enExample)
JP (1) JP5441269B2 (enExample)
KR (1) KR101556808B1 (enExample)
CN (2) CN101481352A (enExample)
AU (1) AU2009207966B2 (enExample)
BR (1) BRPI0907234B1 (enExample)
CA (1) CA2711535C (enExample)
ES (1) ES2533366T3 (enExample)
MX (1) MX2010007553A (enExample)
PT (1) PT2236500E (enExample)
RU (1) RU2488582C2 (enExample)
UA (1) UA101172C2 (enExample)
WO (1) WO2009092276A1 (enExample)
ZA (1) ZA201004794B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0302486D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
CN101921232A (zh) 2009-06-11 2010-12-22 上海恒瑞医药有限公司 双环取代吡唑酮偶氮类衍生物的盐,其制备方法及其在医药上的应用
EP2492262B1 (en) * 2009-10-23 2016-04-20 Nissan Chemical Industries, Ltd. Fused heterocyclic compound and thrombopoietin receptor activator
CN103360317B (zh) * 2012-04-11 2016-12-14 齐鲁制药有限公司 双环取代吡唑酮偶氮类衍生物、其制备方法及用途
CN103724206A (zh) * 2014-01-17 2014-04-16 青岛农业大学 化合物2-溴-4-氟-6-硝基苯酚的制备方法和农用生物活性
WO2015111085A2 (en) * 2014-01-27 2015-07-30 Cadila Healthcare Limited Processes for the preparation of eltrombopag and pharmaceutically acceptable salts, solvates and intermediates thereof
EP3116469B1 (en) 2014-03-10 2018-10-03 Mary Kay, Inc. Skin lightening compositions
CN104592033A (zh) * 2014-12-30 2015-05-06 杭州和泽医药科技有限公司 一种艾曲波帕关键中间体的合成方法
EP3375442A4 (en) * 2016-01-22 2018-12-26 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition comprising bicyclo-substituted pyrazolon azo derivative or salt thereof and preparation method thereof
CN106994120B (zh) * 2016-01-22 2021-05-14 江苏恒瑞医药股份有限公司 一种含有双环取代吡唑酮偶氮类衍生物或其盐的药物组合物及其制备方法
WO2018133818A1 (zh) * 2017-01-19 2018-07-26 江苏恒瑞医药股份有限公司 一种双环取代吡唑酮偶氮类衍生物的制备方法及其中间体
CN110028497B (zh) * 2018-01-11 2020-11-17 江苏恒瑞医药股份有限公司 一种血小板生成素模拟物的乙醇胺盐的结晶形式及制备方法
US20220071961A1 (en) * 2019-01-08 2022-03-10 Jiangsu Hengrui Medicine Co., Ltd. Dosing Regimen of Bicyclic Substituted Pyrazolone Azo Derivative
CN112062699B (zh) * 2020-11-13 2021-02-26 苏州开元民生科技股份有限公司 一种邻氨基苯硫酚的制备方法
WO2022228551A1 (zh) * 2021-04-30 2022-11-03 江苏恒瑞医药股份有限公司 一种血小板生成素受体激动剂的给药方案
WO2023143364A1 (zh) * 2022-01-25 2023-08-03 江苏恒瑞医药股份有限公司 一种血小板生成素受体激动剂的给药方案
WO2025140275A1 (zh) * 2023-12-25 2025-07-03 江苏恒瑞医药股份有限公司 取代吡唑啉偶氮衍生物的磷酸酯化合物或其可药用盐
CN120383561A (zh) * 2025-03-26 2025-07-29 浙江本立科技股份有限公司 一种三氯甲基喹啉和2-取代乙酸联产喹啉酰氯和2-取代乙酰氯的方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB775216A (en) * 1954-02-23 1957-05-22 Sandoz Ltd Improvements in or relating to monoazo dyestuffs of the benzene-azo-pyrazolone series and their chromium-complex compounds
GB806709A (en) * 1955-04-22 1958-12-31 Bayer Ag Monoazo dyestuffs of the benzene-azo-pyrazolone series and metal complexes thereof
US5869451A (en) 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
CN1966520B (zh) 1995-06-07 2012-07-11 葛兰素集团有限公司 结合血小板生成素受体的肽和化合物
JPH111477A (ja) 1997-06-12 1999-01-06 Hokuriku Seiyaku Co Ltd 1,4−ベンゾジアゼピン誘導体及びその用途
WO1999011262A1 (en) 1997-09-02 1999-03-11 Roche Diagnostics Gmbh Mpl-receptor ligands, process for their preparation, medicaments containing them and their use for the treatment and prevention of thrombocytopaenia and anaemia
EP1133291B1 (en) 1998-11-17 2006-01-11 Smithkline Beecham Corporation Cyclic polyamines for treating thrombocytopenia
EP1141909B1 (de) 1998-12-14 2002-09-04 Vodafone AG Verfahren zur übertragung von verkehrsinformationen
GC0000177A (en) 1998-12-17 2006-03-29 Smithkline Beecham Thrombopoietin mimetics
KR20020069183A (ko) 1999-07-26 2002-08-29 시오노기세이야쿠가부시키가이샤 트롬보포이에틴 작동성을 나타내는 의약 조성물
AU770564B2 (en) 1999-09-10 2004-02-26 Smithkline Beecham Corporation Thrombopoietin mimetics
JP2003513965A (ja) 1999-11-05 2003-04-15 スミスクライン・ビーチャム・コーポレイション セミカルバゾン誘導体およびそれらのトロンボポエチン模倣物としての使用
DE60031714T2 (de) 1999-12-06 2007-09-06 Smithkline Beecham Corp. Thrombopoietin-mimetika
TWI284639B (en) 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
CY2010012I2 (el) * 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
MY142390A (en) * 2002-05-22 2010-11-30 Glaxosmithkline Llc 3' - [(2z)-[1-(3,4-dimethylphenyl)-1,5- dihydro-3- methyl-5-0xo-4h-pyrazol-4- ylidene]hydrazino]-2' -hydroxy -[1,1' -biphenyl]-3-carboxylic acid bis-(monoethanolamine)
EP1622609A4 (en) * 2003-04-29 2008-09-03 Smithkline Beecham Corp METHODS OF TREATING DEGENERATIVE DISEASES / LESIONS
EP1701934B1 (en) 2003-12-26 2009-02-25 Allergan, Inc. DISUBSTITUTED CHALCONE OXIMES HAVING RAR(Gamma)-RETINOID RECEPTOR ANTAGONIST ACTIVITY
JP4518819B2 (ja) * 2004-03-17 2010-08-04 富士フイルム株式会社 アゾ化合物
KR101215207B1 (ko) 2004-12-14 2012-12-26 닛산 가가쿠 고교 가부시키 가이샤 아미드 화합물 및 트롬보포이에틴 리셉터 활성화제
WO2007044982A2 (en) * 2005-10-13 2007-04-19 Smithkline Beecham Corporation Methods for the preservation of platelet efficacy during storage
CA2630234A1 (en) * 2005-11-23 2007-05-31 Ligand Pharmaceuticals Inc. Thrombopoietin activity modulating compounds and methods

Also Published As

Publication number Publication date
KR20100120141A (ko) 2010-11-12
EP2236500A1 (en) 2010-10-06
AU2009207966A1 (en) 2009-07-30
US8367710B2 (en) 2013-02-05
CA2711535C (en) 2015-12-15
US20100316601A1 (en) 2010-12-16
KR101556808B1 (ko) 2015-10-01
ZA201004794B (en) 2011-09-28
AU2009207966B2 (en) 2013-03-21
BRPI0907234A2 (pt) 2020-08-04
CA2711535A1 (en) 2009-07-30
EP2236500B1 (en) 2014-12-24
US20130123507A1 (en) 2013-05-16
RU2488582C2 (ru) 2013-07-27
MX2010007553A (es) 2010-10-04
RU2010127786A (ru) 2012-02-20
CN101679286A (zh) 2010-03-24
JP2011509263A (ja) 2011-03-24
JP5441269B2 (ja) 2014-03-12
CN101481352A (zh) 2009-07-15
EP2236500A4 (en) 2012-08-22
ES2533366T3 (es) 2015-04-09
CN101679286B (zh) 2011-06-08
WO2009092276A1 (zh) 2009-07-30
UA101172C2 (ru) 2013-03-11
HK1134818A1 (en) 2010-05-14
PT2236500E (pt) 2015-04-07

Similar Documents

Publication Publication Date Title
JP5441269B2 (ja) ビシクロ置換ピラゾロン−アゾ誘導体、その調製プロセス及び製薬学的使用
JP2011509263A5 (enExample)
RU2538977C2 (ru) Соли бициклозамещенных производных азопиразолона, способ их получения и применение
CN101861312B (zh) 2-[4-(吡唑-4-基烷基)哌嗪-1-基]-3-苯基吡嗪和吡啶及3-[4-(吡唑-4-基烷基)哌嗪-1-基]-2-苯基吡啶作为5-ht7受体拮抗剂
JPH0623193B2 (ja) 新規なジスタマイシンa同族体、その製造方法およびそれを含有する医薬組成物
JPH06510762A (ja) アンジオテンシン2受容体遮断イミダゾリノン誘導体
CN118724877A (zh) 一种作为at2r拮抗剂的杂环化合物
CN119798233A (zh) 一种at2r拮抗剂及其用途
CA2545254A1 (en) Substituted triazoles as sodium channel blockers
CA2521199A1 (en) Pyrazole compounds
CN101679242B (zh) 亚乙基肼酰胺类衍生物、其制备方法及其在医药上的应用
US5049579A (en) Site specific alkylating agents
TWI437985B (zh) 雙環取代吡唑酮偶氮類衍生物、其製備方法及其在醫藥上的應用
HK1134818B (en) Bicyclo-substituted pyrazolon azo derivatives, preparation process and pharmaceutical use thereof
EP1156047B1 (en) 6-substituted-7- heteroquinoxaline carboxylic acid derivatives and addition salts thereof and processes for the preparation of both
MXPA02000317A (es) Benzoilpiridazinas.
TWI530497B (zh) 雙環取代吡唑酮偶氮類衍生物的鹽,及其製備方法和應用
CN106187904A (zh) 含丙炔酰胺基的2-苯基咪唑类衍生物及其制法和药物组合物与用途
TW201032802A (en) Ethylidene hydrazinecarboxamide derivatives, preparation process and pharmaceutical use thereof

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/01/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.